Molbio Diagnostics Limited IPO Overview
Molbio Diagnostics Limited is an Indian medical diagnostics company headquartered in Verna, Goa, that develops molecular diagnostic technologies. Founded in 2000, the company developed the Truenat platform — a portable real-time PCR system used to diagnose infectious diseases including tuberculosis, HIV, and hepatitis. Its flagship product, Truenat, is a portable, battery-operated PCR-based molecular diagnostics platform capable of delivering test results within an hour. Developed through 13 years of research and development, Truenat has received ICMR certification for tuberculosis testing and is one of only two rapid molecular diagnostic platforms globally endorsed by the World Health Organisation (WHO) for the initial detection of tuberculosis and rifampicin resistance.
Molbio provides molecular testing solutions covering more than 30 diseases through 43 diagnostic assays and operates six manufacturing facilities in India, serving customers across more than 90 countries.
The company is now launching its Mainboard IPO on BSE and NSE. The IPO aims to raise approximately ₹939.70 crore, comprising a fresh issue of ₹200 crore and an offer for sale of 91,66,000 equity shares worth approximately ₹739.70 crore. The price band is set at ₹768 to ₹807 per share, with a lot size of 18 shares, making the minimum retail investment approximately ₹14,526. The IPO opens on 10 August 2026 and closes on 12 August 2026, with listing expected on 17 August 2026.
IPO Detailed Information
Issue Details
| Parameter | Details |
| IPO Type | Book Built – Mainboard |
| Listing Exchange | BSE & NSE |
| IPO Open Date | 10 August 2026 |
| IPO Close Date | 12 August 2026 |
| Allotment Date | 13 August 2026 (Expected) |
| Refund Initiation | 14 August 2026 |
| Credit to Demat | 14 August 2026 |
| Listing Date | 17 August 2026 (Tentative) |
| Price Band | ₹768 – ₹807 per share |
| Face Value | ₹1 per share |
| Lot Size | 18 shares |
| Minimum Investment (Retail) | ₹14,526 (approx) |
| Issue Size | ₹939.70 crore |
| Fresh Issue | 24,80,246 shares (₹200 crore) |
| Offer For Sale (OFS) | 91,66,000 shares (₹739.70 crore) |
Note: The IPO comprises a fresh issue of 24,80,246 shares worth approximately ₹200 crore, and an offer for sale of 91,66,000 shares worth approximately ₹739.70 crore. A large portion of the IPO proceeds will therefore go to existing investors and promoters, not the company.
Issue Break-up
| Category | Allocation |
| Qualified Institutional Buyers (QIB) | ~50% |
| Non-Institutional Investors (NII/HNI) | ~15% |
| Retail Individual Investors (RII) | ~35% |
OFS / Selling Shareholders
Among the selling shareholders are Exxora Trading LLP, Dr. Chandrasekhar Bhaskaran Nair, V Sciences Investments Pte. Ltd., and India Business Excellence Fund III, alongside other long-term shareholders. The OFS provides a partial exit to early investors and certain promoter group members. Of the total ₹939.70 crore raised, approximately ₹739.70 crore will go to OFS sellers, not to the company.
Objects of the Issue (Fund Utilization)
The company will receive only the ₹200 crore fresh issue proceeds. These will be used as follows:
- Funding capital expenditure towards setting up of infrastructure for the R&D facility, Centre of Excellence, and connected office space — ₹105.54 crore
- Funding capital expenditure towards purchase of plant, machinery, and other equipment for Goa Unit I, Goa Unit II, and Visakhapatnam Unit — ₹72.28 crore
- General corporate purposes — remaining proceeds
Lead Managers & Registrar
- Book Running Lead Managers: Kotak Mahindra Capital Company Ltd., IIFL Capital Services Ltd., Jefferies India Private Ltd., and Motilal Oswal Investment Advisors Ltd.
- Registrar to the Issue: Kfin Technologies Ltd.
- Email: [email protected]
Promoters & Management
The promoters are Sriram Natarajan, Dr. Chandrasekhar Bhaskaran Nair, Sangeetha Sriram, Shiva Sriram, Sowmya Sriram, and Exxora Trading LLP. As of the DRHP filing date, these promoters collectively hold 46.65% of the pre-IPO equity share capital.
Registered Address: Plot No. L-46, Phase II-D, Verna Industrial Area, Verna, Salcete, South Goa — 403722
Company Details
Incorporated in 2000, Molbio Diagnostics Limited is a point-of-care molecular diagnostics company engaged in research, development, manufacturing, and commercialisation of diagnostic solutions for infectious and non-communicable diseases. Its flagship Truenat platform is a portable, battery-operated PCR-based molecular diagnostics system capable of providing accurate test results within approximately one hour.
Sectors / Customers Served:
- Government health programmes (central and state)
- Hospitals and diagnostic laboratories
- International health organisations and global aid agencies
- Rural and resource-limited healthcare settings
Key Products:
- Truenat platform — comprising the Trueprep (nucleic acid extraction device) and Truelab Analyzer (portable PCR analyzer)
- Patented in more than 100 countries, Truenat enables testing for tuberculosis, HIV, malaria, viral hepatitis, COVID-19, dengue, chikungunya, influenza (including H1N1), HPV high-risk, cholera, leprosy, and non-infectious markers such as HLA-B27
Key Capabilities:
- Testing solutions covering more than 30 diseases through 43 diagnostic assays
- Six manufacturing facilities in India (Goa, Bengaluru, Visakhapatnam)
- Six subsidiaries including Bigtec Pvt. Ltd. and Prognosys Medical Systems Pvt. Ltd., covering diagnostics, medical systems, and related technologies
- International distribution supported through global health programmes across 90+ countries
Certifications / Recognitions:
- WHO-endorsed platform for tuberculosis detection and rifampicin resistance
- ICMR certified for tuberculosis testing
- Patents in 100+ countries
Financial Snapshot
| Period | Total Income (₹ Cr) | PAT (₹ Cr) |
| FY25 | ₹1,027.94 | ₹138.58 |
| FY26 | ₹1,455.17 | ₹164.14 |
Key Financial Metrics
- Total income grew from ₹1,027.94 crore in FY25 to ₹1,455.17 crore in FY26 — a growth of approximately 42%. PAT grew from ₹138.58 crore to ₹164.14 crore.
- Revenue from operations grew at a 3-year CAGR of approximately 31.40%.
- EBITDA margin: 22.56% — reflecting strong operational efficiency.
- Market capitalisation at upper price band (₹807): ~₹9,300 crore
- Operating cash flow declined from ₹287.10 crore in FY25 to ₹50.39 crore in FY26, despite strong revenue performance — a key concern for investors.
Company Strengths
- Proprietary Truenat platform — one of only two rapid molecular diagnostic platforms globally endorsed by WHO for tuberculosis detection; also ICMR certified, making it deeply embedded in national and global health programmes.
- Patented in more than 100 countries, offering a strong competitive moat and high barrier to entry in the point-of-care molecular diagnostics space.
- Competitive edge lies in robust R&D capabilities and a wide distribution network catering to both urban and rural healthcare settings.
- Serves customers across more than 90 countries with six manufacturing facilities in India — providing geographic and operational scale.
- Strong and consistent revenue growth with a 3-year CAGR of ~31.40% in revenue from operations
- Diversified subsidiary structure including Bigtec Pvt. Ltd. and Prognosys Medical Systems Pvt. Ltd., covering diagnostics, medical systems, and adjacent technologies.
Key Risks & Challenges
- High government dependency — 84.56% of FY26 revenue was derived from Indian central/state governments and international aid agencies. Any policy changes could significantly impact sales.
- Operating cash flow declined sharply from ₹287.10 crore in FY25 to ₹50.39 crore in FY26, despite strong revenue performance — raising concerns about cash conversion quality.
- High inventory levels of ₹435.91 crore as of March 31, 2025. Since the specialised Truenat kits have a limited shelf life of only two years, inaccurate demand forecasting can lead directly to material losses.
- Concentrated supplier base — raw material purchases from top 10 suppliers accounted for 58.21% of total consumption in FY25, posing supply chain risk.
- OFS-heavy IPO: Of the total ₹939.70 crore raised, approximately ₹739.70 crore (79%) goes to selling shareholders — limiting fresh capital inflow to the company.
- R&D and product approval risk — the company depends on successful R&D and timely regulatory approvals for new diagnostic tests. Failure to develop or obtain approvals could impact growth.
Disclaimer:
This document is for informational purposes only and should not be considered as investment advice. Investors should read the Red Herring Prospectus (RHP) carefully and consult a financial advisor before investing in any IPO. Market investments are subject to risk.
